Separate terms with OR to return results that match either term.
 
Clear All

9,635 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00007-3262-01 00007-3262 Tositumomab, Iodine I-131 Bexxar Therapeutic Immunotherapy Radioimmunotherapy CD20 July 15, 2009 Feb. 20, 2014 No Longer Used
00007-3261-01 00007-3261 Tositumomab, Iodine I-131 Bexxar Dosimetric Immunotherapy Radioimmunotherapy CD20 July 15, 2009 Feb. 13, 2014 No Longer Used
00007-3260-31 00007-3260 Tositumomab Bexxar Immunotherapy Radioimmunotherapy CD20 July 15, 2009 Nov. 28, 2014 No Longer Used
00007-3260-36 00007-3260 Tositumomab Bexxar Immunotherapy Radioimmunotherapy CD20 July 15, 2009 Nov. 28, 2014 No Longer Used
00054-0399-25 00054-0399 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2020 In Use
00832-0285-00 00832-0285 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral July 25, 2018 In Use
69238-1250-01 69238-1250 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sept. 4, 2018 In Use
43975-0315-10 43975-0315 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral May 10, 2018 In Use
00378-6955-01 00378-6955 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral July 9, 2015 In Use
68682-0003-10 68682-0003 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 17, 2015 In Use
00591-2832-01 00591-2832 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 11, 2021 In Use
42292-0007-01 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 15, 2016 Jan. 31, 2020 No Longer Used
42292-0007-10 42292-0007 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral April 15, 2016 Jan. 31, 2020 No Longer Used
68682-0002-60 68682-0002 Bexarotene Bexarotene 1.0 g/100g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical June 28, 2000 In Use
69238-2088-06 69238-2088 Bexarotene Bexarotene 10.0 mg/g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical May 4, 2022 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug. 18, 2017 In Use
63459-0348-04 63459-0348 Bendamustine Hydrochloride Bendeka 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 8, 2015 In Use
67457-0325-12 67457-0325 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 26, 2018 Feb. 21, 2019 In Use
67457-0326-05 67457-0326 Bendamustine Hydrochloride Bendamustine Hydrochloride 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 26, 2018 Feb. 21, 2019 In Use
68152-0108-09 68152-0108 Belinostat Beleodaq 500.0 mg/10mL Chemotherapy Enzyme Inhibitor HDAC Intravenous July 21, 2014 Nov. 30, 2022 In Use
64679-0810-08 64679-0810 Dexamethasone Baycadron 0.5 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral July 27, 1983 In Use
44087-3535-01 44087-3535 Avelumab Bavencio 20.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 23, 2017 In Use
62756-0452-36 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use
62756-0452-37 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use
72579-0011-01 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 Sept. 30, 2021 In Use
72579-0011-02 72579-0011 Zanubrutinib BRUKINSA 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Nov. 14, 2019 In Use
73153-0900-01 73153-0900 Lisocabtagene maraleucel BREYANZI Immunotherapy CAR-T CD19 Feb. 5, 2021 In Use
70255-0025-01 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-03 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 In Use
70255-0025-05 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
70255-0025-06 70255-0025 Encorafenib BRAFTOVI 75.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral Aug. 3, 2020 In Use
70255-0020-01 70255-0020 Encorafenib BRAFTOVI 50.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 March 13, 2019 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
10019-0991-01 10019-0991 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70710-1411-01 70710-1411 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
70771-1708-01 70771-1708 BORTEZOMIB BORTEZOMIB 1.0 mg/mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
73536-0500-01 73536-0500 ROPEGINTERFERON ALFA-2B BESREMi 500.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 12, 2021 In Use
42367-0520-25 42367-0520 bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 15, 2018 Sept. 30, 2020 No Longer Used
42367-0521-25 42367-0521 Bendamustine Hydrochloride BELRAPZO 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 3, 2019 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use

Found 9,635 results in 18 millisecondsExport these results